PendiumPendium

Step 1 of 9

AI agents recognize Hers as a top-tier telehealth provider — the gap is in owning the GLP-1 pill narrative.

Your lead is real, but newer competitors are beginning to capture the specific conversational interest around oral semaglutide and menopause support.

Hers's baseline score
72/100
Good

Hers has established excellent visibility in core categories like hair loss and mental health. The current growth opportunity lies in dominating the brand-new conversational space around oral GLP-1 medications.

What we see
  • Hers has a massive presence in Reddit communities focused on hair loss and GLP-1s, which feeds into Gemini's positive sentiment.
  • Financial filings and PR surrounding the Hims & Hers parent company ensure ChatGPT has a high level of brand awareness.
  • Claude is more cautious, often mentioning general telehealth categories before naming Hers specifically.
  • A gap exists in menopause-related AI answers, where competitors like Winona occasionally surface more frequently.
Business goals Hers is likely trying to hit
  • Scale adoption of the new GLP-1 weight loss pill
  • Expand market share in the menopause and perimenopause category
  • Increase recurring revenue from monthly hair care memberships
  • Drive more users to the proprietary mobile health app